Research Abstracts Online
January - December 2011
University of Minnesota Duluth
College of Pharmacy Duluth
of Pharmacy Practice and Pharmaceutical Sciences
PI: Michael T. Swanoski
A Cross-Sectional Study Examining the Prevalence of U.S. Adults Who Smoke Receiving the Pneumococcal Polysaccharide Vaccine
In October 2008, the U.S. Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP) voted to recommend that people 19 to 64 years of age who smoke cigarettes receive pneumococcal polysaccharide vaccine (PPSV23), known as PNEUMOVAX® 23 (Pneumococcal Vaccine Polyvalent). This was the first time that the ACIP recommended a vaccine specifically for people who smoke. The recommendation was made due to growing evidence that cigarette smokers were at increased risk for invasive pneumococcal disease. Data has shown that smokers are approximately four times more likely to develop pneumococcal disease than non-smokers and that the likelihood increases as a person smokes more cigarettes. Data has also shown that smoking was significantly associated with invasive pneumococcal disease, which includes other potentially serious infections such as meningitis or bacteremia.
These researchers are investigating the 2010 prevalence of U.S. adults who smoke receiving a pneumococcal polysaccharide vaccine and whether the 2010 prevalence is significantly higher than the prevalence in 2005. They are also determining whether these prevalence rates vary significantly between rural and non-rural populations.
Daniel Filipiak, Staff